Studies Seek to Find Female Biologic Factors That Affect HIV

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

BETHESDA, Maryland-A 5-year, $17.5-million program will investigate how HIV infection affects adolescent and adult women. Three research centers will house the Women’s HIV Pathogenesis Program, funded by the National Institute of Child Health and Human Development (NICHD). Researchers at the centers will collaborate with others in an effort to identify biologic factors unique to women that affect HIV.

BETHESDA, Maryland—A 5-year, $17.5-million program will investigate how HIV infection affects adolescent and adult women. Three research centers will house the Women’s HIV Pathogenesis Program, funded by the National Institute of Child Health and Human Development (NICHD). Researchers at the centers will collaborate with others in an effort to identify biologic factors unique to women that affect HIV.

The centers will be located at the University of Washington in Seattle, the Gladstone Institute of Virology in San Francisco, and Rush-Presbyterian-St. Luke’s Medical Center in Chicago.

Researchers will focus on various subpopulations, including minority women, lesbians, female substance abusers, and women approaching or experiencing menopause. Understanding biologic factors unique to women could provide insights into how they become infected with the virus and transmit it to others, how the disease progresses in women after infection takes place, and how the disease affects women differently from men, NICHD said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.